Calvagone's Team of Experts



Stéhanie graduated with a Master in Public Health, Biostatistics specialty, in 2011 from the University of Lyon. She completed a PhD entitled « Predicting and estimating the potential impact of multiple interventions on HIV incidence, Ndhiwa sub-county, Kenya » from the University of Lyon in 2015. Her PhD thesis focused on the mathematical modelling of HIV spreading in hyper-endemic settings in sub-Saharan Africa. She then joined the Centre for Health Economics Research and Modelling Infectious Diseases (University of Antwerp, Belgium) as a post-doctoral researcher. She then joined Avadel Research (Avadel Pharmaceuticals, Vénissieux, France) as a PK and Biostatistics scientist. She is author of several research papers.

Stéphanie started her collaboration with Calvagone in February 2020, and has joined as a consultant in September 2020. She lives in France, near Lyon.



Emilie obtained a Master in Engineering in Biosciences, Bioinformatics and Modelling from the National Institute of Applied Sciences of Lyon in 2005, and an MSc in Pharmacology and Pharmacometrics from the University of Lyon in 2005. After completing her PhD entitled “Study by modelling and simulation of the impact on efficacy and toxicity of non-compliance to oral anticancer drugs” from the University of Lyon in 2008, Emilie joined the Pharmacometrics Group from Uppsala University, as a postdoctoral fellow. Between 2011 and 2015, Emilie was a hospital-university researcher and lecturer in Pharmacology and Pharmacometrics at the University of Lyon, with projects oriented towards the characterization of the dose- response relationships and therapeutic optimization using pharmacometrics, particularly in oncology and in paediatrics. She acted as an expert in pharmacometrics within the paediatric section of the clinical investigation centre of the hospital of Lyon. She has also trained and supervised Msc students and PhD candidates in pharmacometrics, and obtained her accreditation to supervise research in 2013. Her research has been credited by several distinctive awards, including the Lewis Sheiner Student award (PAGE 2006 as PhD candidate, and PAGE 2014 as PhD supervisor), and the AAPS Graduate Student Award (AAPS 2008).
She is author and co-author of 50+ research articles published in international peer-reviewed journals.

Emilie joined Calvagone as a senior consultant in November 2015. Since February 2024, Emilie is also Director of Operations. She lives in France, near Lyon.

Christian LAVEILLE


Christian obtained his Pharm.D. degree from the University of Lyon in 1985 with a specialization in pharmacokinetics, pharmacology and toxicology in 1986. Christian joined Servier in 1989 where he started as a pharmacokineticist. In 1991 he moved to the University of California, San Francisco, for a training period where he studied both the methodological and practical aspects of utilizing mixed effects modelling. He returned to France in 1992 and started to implement mixed effects modelling within Servier. Christian held several posts within the Division of Pharmacokinetics, which involved population PK/PD analysis for a variety of compounds in a range of therapeutic classes (e.g. endocrinology, CNS, cardiovascular). In the last one and a half year at Servier, he was responsible for the Clinical Pharmacokinetics Department. Christian subsequently worked at Exprimo from 2005-2015 as senior consultant and eventually as Scientific Director, hugely expanding his modelling and simulation expertise. He has more than 30 years of drug development experience within the pharmaceutical industry and has also contributed to several registration dossiers for new drug applications. Christian is (co) author of numerous papers in the field of pharmacokinetics and pharmacodynamics.

Christian founded Calvagone in November 2015.
In a desire to reduce his involvement in day-to-day business and hands-on projects, Christian transitioned, since February 2024, to a role as Executive Consultant, supporting the Calvagone team as an advisor and mentor. He lives in France, near Lyon.



Andreas studied pharmacy at the University of Bonn where he obtained his license in 2006. Thereafter he started his PhD research at the Department of Clinical Pharmacy at the same university, focusing on PK/PD modelling in oncology and CNS. He completed his research with his thesis entitled: « Pharmacokinetic/Pharmacodynamic Modelling and Simulation of Biomarker Response to Venlafaxine and Sunitinib Administration ». In 2009, he moved to Barcelona where he joined Ferrer Internacional, as a pharmacometrician in the Department of Drug Metabolism and Pharmacokinetics. At Ferrer he was mainly working on the development of anti-infective agents and drugs for the treatment of sleep disorders. In 2011, Andreas joined Merck, Sharp & Dohme in Oss, The Netherlands. There he worked in several multi-disciplinary clinical development teams (early stage) where he was responsible for the planning and conduct of PK/PD and M&S related activities. In addition, he performed M&S analyses in several therapeutic areas including oncology, CNS, infectious diseases, cardiovascular diseases and hematology. From 2014 until 2019 he worked as a senior consultant at SGS Exprimo, on a variety of M&S projects in diverse areas including epilepsy, pain, oncology and endocrinology for large and small companies.

Andreas has an assignment as senior consultant for Calvagone since February 2019. Since February 2024, Andreas is also Scientific Director. He lives in Spain, near Barcelona.



Sarah graduated with a Pharm.D. degree from Rennes University, France, in 2019. During her pharmaceutical studies, she completed two master's degrees in Pharmacology and in Pharmacometrics, respectively from Strasbourg University in 2018 and from Paris Descartes University in 2019. During this period, she gained valuable industry experience through internships at Servier and Novartis. At Servier, Sarah developed PBPK models to assess drug-drug interactions with anticancer drug candidates. During her internship at Novartis, she contributed to translational approaches in oncology, focusing on developing joint PK-tumor growth inhibition models based on preclinical data to explore synergistic effects and inform dose determination for clinical trials. She obtained her Ph.D. in Pharmacometrics from Tours University, France, in 2023, focusing on the exposure-response relationship of therapeutic monoclonal antibodies (mAb) in metastatic colorectal cancer. Her work involved the development of popPK and PKPD models, including target-mediated drug disposition (TMDD) and joint TMDD-time-to-event models, and the use of strategies to mitigate potential cofounding factors, based on phase II clinical trial data. Additionally, she conducted research on the influence of body composition parameters on mAb pharmacokinetic variability based on computed tomography scan images and retrospective hospital data. Sarah has presented her findings at various conferences, including the PAGE meeting. Since 2021, she has been an active member of the scientific committee of the Group of Metabolism and Pharmacokinetic (GMP).

Sarah joined Calvagone as an associate consultant in March 2024. She lives in Rennes, France.

Nicolas LUYCKX


Nicolas obtained a Dual Master degree in Electrical engineering from the universities of Louvain-La-Neuve and Leuven, with option Multimedia and Signal Processing. He is an enthusiastic, innovative and skilled engineer with more than 10 years of experience in software development. After several years of working in the railway field, Nicolas discovered Modelling & Simulation by joining SGS Exprimo in 2017, and became passionate about it. At SGS Exprimo he was a developer of Simulo, a clinical trial simulator that allows various model-based simulation activities. He cooperated on many simulation projects for clients and in various fields, among others: extrapolation from adult PK for pediatric studies, evaluation of optimal design for planned studies and evaluation of various dosing scenarios and algorithms to comply with efficacy and safety requirements. Nicolas also collaborated in the development of a Therapeutic Drug Monitoring (TDM) R package, in collaboration with the university of Leuven. Given his past experience in IT and his recent experience in M&S, Nicolas understands how powerful software engineering and process automation can be for pharmacometrics.

Nicolas joined Calvagone as a consultant in February 2021 to provide continuous IT engineering support and develop tools in order to improve productivity and efficiency. He lives in Belgium, near Louvain-La-Neuve.

Pierre-Alexandre NOGUINE


Pierre-Alexandre obtained a Technical degree in Biophysics from E.T.S.L (Ecole Technique Supérieure du Laboratoire) Paris in 1989 followed by post graduate training in Biology, Mathematics and Statistics from C.N.A.M (Conservatoire National des Arts et Métiers) Paris in 1990. Pierre-Alexandre joined Servier Laboratories in 1990 where he started as a Data Manager on clinical trials and later was involved in generating SAS outputs for clinical reports. In 1997, Pierre-Alexandre joined the QA department at Servier where he was in charge of GCP IT audits. In 2004, he joined the Pharmacokinetic department in the same company as an IT Project Leader involved in SAS programming, data extractions, validation and administration of NONMEM and WINNONLIN. Pierre-Alexandre worked at Exprimo from 2009-2015 as a consultant and was in charge of programming with SAS, R and Visual Studio.

Pierre-Alexandre joined Calvagone as a senior consultant in November 2015. He lives in France, near Paris.

Melanie RINAS


Melanie studied Mathematics at the University of Tübingen in Germany. In 2009, she started her PhD research in Computational Biology at the German Cancer Research Center (DKFZ) and the University of Heidelberg in Germany. Here, she analysed virus-host interactions using data-driven modelling and simulation (M&S). After obtaining her PhD, she worked as a Postdoc in Computational Biomedicine on the mathematical modelling of signalling networks in Multiple Sclerosis at the RWTH Aachen University Hospital and the BioQuant in Heidelberg, Germany. In 2019, she moved to industry and joined Trium Analysis Online GmbH in Munich, Germany, as a Data Scientist Analytics. Here, she was responsible for the data systems of clinical studies and the management of a wearable device for real-world monitoring of human motion during clinical trials. From 2021 to 2023, she worked remotely as a Pharmacometrician at AbbVie in Germany and performed pharmacometrics (PMx) analyses to support drug development for various indications and different clinical studies. Afterward, she joined Parexel as a Senior Pharmacokinetic (PK) Scientist to analyse clinical pharmacokinetic/pharmacodynamic (PK/PD) data using M&S.

Since May 2024, Melanie works at Calvagone as a Consultant. She lives in Bad Saulgau, Germany.

Sajid Ali SHAH


Sajid Ali Shah obtained his PharmD degree from Dow University of Health Sciences, Karachi, Pakistan in 2018 focusing mainly in Clinical Pharmacology. He graduated with a Master degree in Pharmaceutical Modelling from Uppsala University, Sweden with a major in physiologically based pharmacokinetic (PBPK) modelling and Pharmacometrics. His Master thesis focused on "PBPK modelling of lactation in milk-producing animals: a case study of oxytetracycline and tylosin". He then joined Puissan Biotech (Helsinki, Finland) as a PBPK Scientist where the focus was on PBPK modelling projects supporting clients, as well as the development of the company's existing PBPK software "Skin-in-Silico" for topical formulations. He is innovative and enthusiastic with a strong interest in PBPK and pharmacometrics modelling and simulation.

Sajid started collaboration with Calvagone in September 2023 as Associate Consultant. He lives in Helsinki, Finland.



Erno obtained a MSc in Bio-pharmaceutical Sciences from Leiden University, the Netherlands in 1992 and obtained his PhD from Leiden University in 1997. The emphasis of his PhD research, a collaboration with Glaxo (now GSK) in the UK, was on the application of mechanism-based PK/PD modelling to assess the in vivo selectivity of novel purinergic drugs. In 1996 Erno joined the department of clinical pharmacokinetics at J&J in Belgium supporting clinical development programs of CNS compounds and global pharmacometric strategies for novel antidepressants and anxiolytics. From 2000 Erno worked in early clinical development, where he developed an interest in the application of translational pharmacometric approaches to facilitate transfer of compounds from animal to man. In 2003, he joined Tibotec/Virco as clinical pharmacologist with the aim to develop population PK(/PD) approaches to guide personalized HIV-therapy. From 2004 onwards Erno worked as senior consultant at Exprimo specializing in the implementation of modelling and simulation in drug development and eventually as managing director of Exprimo from 2015 to 2016. Erno is author of several research papers on the application of pharmacokinetic-pharmacodynamic modelling and mixed effects analyses.

Erno joined Calvagone as a senior consultant in January 2017. Since February 2024, Erno is also Managing Director. He lives in The Netherlands, near Breda.